Pre-made Gedivumab benchmark antibody ( Whole mAb, anti-Influenza A HA therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Gedivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

39.29 (gedivumab) is fully human neutralizing monoclonal antibody against influenza A. 39.29 is a neutralizing monoclonal antibody that recognizes the hemagglutinin (HA) glycoprotein of all 16 subtypes and neutralized both group 1 and group 2 influenza A viruses.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-238-1mg	1mg	3090
GMP-Bios-ab-238-10mg	10mg	Inquiry
GMP-Bios-ab-238-100mg	100mg	Inquiry
GMP-Bios-ab-238-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Gedivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody
INN Name	Gedivumab
Target	Influenza A HA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	4kvn:HL
Year Proposed	2016
Year Recommended	2017
Companies	Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Influenza A virus infections
Development Tech	na